Valuation: Allergy Therapeutics plc

Market Cap 332M 452M 388M 362M 625M 43.24B 635M 4.28B 1.67B 21.69B 1.7B 1.66B 71.7B P/E 2026 *
-5.77x
P/E 2027 * -
Enterprise Value 377M 513M 440M 411M 708M 48.99B 720M 4.84B 1.9B 24.57B 1.92B 1.88B 81.24B EV / Sales 2026 *
6.29x
EV / Sales 2027 * -
Free-Float
11.23%
Yield 2026 *
-
Yield 2027 * -
1 day+2.67%
1 week+2.67%
Current month-9.87%
1 month-17.08%
3 months-44.32%
6 months-48.17%
Current year-51.00%
1 week 5.28
Extreme 5.275
5.5
1 month 5
Extreme 5
6.8
Current year 5
Extreme 5
12.1
1 year 5
Extreme 5
12.1
3 years 1.2
Extreme 1.2
12.1
5 years 0.8
Extreme 0.8
40.5
10 years 0.8
Extreme 0.8
40.5
Manager TitleAgeSince
Chief Executive Officer 62 01/09/2009
Director of Finance/CFO - 11/08/2023
Corporate Officer/Principal - 01/05/2013
Director TitleAgeSince
Director/Board Member 62 01/09/2009
Chairman 75 04/01/2011
Director/Board Member 69 06/06/2017
Date Insider Type Main position Quantity % Market Cap.
13/06/26 Free

Chief Financial Officer

2,300,000 0.0363%
12/03/26
ZQ Capital Ltd.
OthersCompany 1,993,473,455 32.4594%
12/03/26
ZQ Capital Ltd.
OthersCompany 150,925,926 2.4575%
Change 5-day change 1-year change 3-year change Capi.($)
+2.67%+2.67%-38.05%+111.37% 452M
-0.58%+5.37%+47.06%+3.50% 83.96B
+2.84%+24.49%-22.44%-35.85% 56.76B
+0.85%-0.32%-1.93%+30.25% 51.35B
-0.14%-0.78%+11.37%+166.75% 48.41B
-1.07%+6.08%+59.56%-15.16% 32.74B
-17.07%+173.88%+524.79%+71.60% 69.62B
-1.46%+6.38%+50.33%+100.61% 26.04B
+3.00%+6.36%+6.92%+224.88% 21.81B
-1.31%+2.05%+61.08%+123.10% 17.11B
Average -1.28%+21.75%+69.87%+78.11% 40.83B
Weighted average by Cap. -2.70%+34.56%+108.03%+54.02%

Financials

2026 *2027 *
Net sales 59.9M 81.51M 69.92M 65.29M 113M 7.79B 114M 770M 302M 3.91B 306M 299M 12.92B -
Net income -55.7M -75.79M -65.02M -60.71M -105M -7.24B -106M -716M -281M -3.63B -285M -278M -12.01B -
Net Debt 44.2M 60.15M 51.59M 48.18M 83.12M 5.75B 84.49M 568M 223M 2.88B 226M 221M 9.53B -
Logo Allergy Therapeutics plc
Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. It sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. It sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.
Employees
584
Date Price Change Volume
20/08/26 GBX 5.390 +2.67% 20,000
19/08/26 GBX 5.250 0.00% 4,138
18/08/26 GBX 5.250 0.00% 19,451
17/08/26 GBX 5.250 0.00% 21,183
14/08/26 GBX 5.250 0.00% 195,702
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0525GBP
Average target price
0.1300GBP
Spread / Average Target
+147.62%

Annual profits - Rate of surprise